Aptevo Therapeutics, Inc. (APVO)
1.77
+0.01
(+0.57%)
USD |
NASDAQ |
Oct 05, 10:29
Aptevo Therapeutics Net Income (Quarterly) : -6.356M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -6.356M |
| March 31, 2026 | -6.794M |
| December 31, 2025 | -5.806M |
| September 30, 2025 | -9.028M |
| June 30, 2025 | -6.204M |
| March 31, 2025 | -6.408M |
| December 31, 2024 | -6.312M |
| September 30, 2024 | -5.101M |
| June 30, 2024 | -5.883M |
| March 31, 2024 | -6.834M |
| December 31, 2023 | -6.196M |
| September 30, 2023 | -6.334M |
| June 30, 2023 | -7.948M |
| March 31, 2023 | 1.827M |
| December 31, 2022 | -5.163M |
| September 30, 2022 | -7.809M |
| June 30, 2022 | 27.86M |
| March 31, 2022 | -7.875M |
| December 31, 2021 | -6.597M |
| September 30, 2021 | -7.077M |
| June 30, 2021 | -8.064M |
| March 31, 2021 | -7.67M |
| Date | Value |
|---|---|
| December 31, 2020 | -7.171M |
| September 30, 2020 | -6.948M |
| June 30, 2020 | -6.803M |
| March 31, 2020 | -10.00M |
| December 31, 2019 | -9.398M |
| September 30, 2019 | -11.08M |
| June 30, 2019 | -10.84M |
| March 31, 2019 | -11.74M |
| December 31, 2018 | -14.02M |
| September 30, 2018 | -12.56M |
| June 30, 2018 | -13.14M |
| March 31, 2018 | -13.85M |
| December 31, 2017 | -9.695M |
| September 30, 2017 | 2.984M |
| June 30, 2017 | -14.17M |
| March 31, 2017 | -11.71M |
| December 31, 2016 | -16.16M |
| September 30, 2016 | -73.41M |
| June 30, 2016 | -12.84M |
| March 31, 2016 | -12.89M |
| March 31, 2015 | -11.02M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | -178.92M |
| Oncolytics Biotech, Inc. | -9.442M |
| Sangamo Therapeutics, Inc. | -31.00M |
| Sarepta Therapeutics, Inc. | -4.89M |
| Anixa Biosciences, Inc. | -2.625M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 6.356M |
| EPS Diluted (Quarterly) | -5.313 |
| Enterprise Value | -3.091M |
| Earnings Yield | -3.26K% |
| Normalized Earnings Yield | -3263.44 |